Cargando…
Moderate Hypofractionated Helical Tomotherapy for Older Patients with Localized Prostate Cancer: Long-term Outcomes of a Phase I–II Trial
BACKGROUND: Our previous study showed that two different regimens of moderate hypofractionated radiotherapy (HFRT) delivered with helical tomotherapy (HT) are well tolerated in older prostate cancer patients. We provide a longterm efficacy and toxicity after > 7 years of follow-up. PATIENTS AND M...
Autores principales: | Cui, Di, Du, Lei, Yu, Wei, Cai, Boning, Meng, Lingling, Yang, Jun, Luo, Yanrong, Chen, Jing, Ma, Lin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sciendo
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122298/ https://www.ncbi.nlm.nih.gov/pubmed/35344645 http://dx.doi.org/10.2478/raon-2022-0011 |
Ejemplares similares
-
Dosimetric comparison among cyberknife, helical tomotherapy and VMAT for hypofractionated treatment in localized prostate cancer
por: Serra, Marcello, et al.
Publicado: (2020) -
Tomotherapy-based moderate hypofractionation for localized prostate cancer: a mono-institutional analysis
por: Tenti, Maria Valentina, et al.
Publicado: (2022) -
Image Guided Hypofractionated Radiotherapy by Helical Tomotherapy for Prostate Carcinoma: Toxicity and Impact on Nadir PSA
por: Barra, Salvina, et al.
Publicado: (2014) -
Hypofractionated postoperative helical tomotherapy in prostate cancer: a mono-institutional report of toxicity and clinical outcomes
por: Cuccia, Francesco, et al.
Publicado: (2018) -
The Acute Toxicities and Efficacy of Concurrent Chemotherapy With Docetaxel Plus Cisplatin, or Docetaxel, or Cisplatin and Helical Tomotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized Single-Center Phase II Trial
por: Luo, Yanrong, et al.
Publicado: (2022)